Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Critical Care Medicine, NIH, Bethesda, MD, USA.
Am J Nephrol. 2013;37(5):443-51. doi: 10.1159/000350384. Epub 2013 Apr 20.
BACKGROUND/AIMS: Microalbuminuria is a marker for early kidney disease and cardiovascular risk. The purposes of this study were to determine the prevalence of microalbuminuria in an HIV-infected clinic population, to test the predictive value of a single urine albumin/creatinine ratio (ACR) to identify persistent microalbuminuria and to examine covariates of microalbuminuria.
We conducted a prospective cohort study of HIV-infected subjects (n = 182) without proteinuria (urine protein/creatinine ratio ≥0.5 g/g), elevated serum creatinine, diabetes, or chronic inflammatory conditions. Subjects completed three research visits within 9 months. Microalbuminuria was defined as the geometric mean ACR of 25-355 mg/g for females and 17-250 mg/g for males.
The prevalence of microalbuminuria was 14%. The negative predictive value of a single urine ACR determination was 98%, whereas the positive predictive value was only 74%. Microalbuminuria was similar among Black (15%) and non-Black (14%) subjects (p = 0.8). Subjects with microalbuminuria were more likely to have hypertension (p = 0.02) and metabolic syndrome (p = 0.03). While duration of HIV infection and the level of HIV viremia were similar between groups, those with microalbuminuria were more likely to have a CD4 count <200 cells/μl (p = 0.0003). In a multivariate logistic regression analysis, the only significant independent predictors of microalbuminuria were low CD4 count (p = 0.018) and current ritonavir exposure (p = 0.04).
The prevalence of microalbuminuria in an HIV-infected clinic population was similar to earlier reports, and was associated with hypertension and impaired immune function. A single normal ACR determination effectively excludes microalbuminuria, whereas an elevated ACR requires confirmation.
背景/目的:微量白蛋白尿是早期肾脏疾病和心血管风险的标志物。本研究的目的是确定感染艾滋病毒的临床人群中微量白蛋白尿的患病率,检验单次尿白蛋白/肌酐比值(ACR)预测持续性微量白蛋白尿的价值,并研究微量白蛋白尿的相关因素。
我们对 182 名无蛋白尿(尿蛋白/肌酐比值≥0.5 g/g)、血清肌酐升高、糖尿病或慢性炎症的感染艾滋病毒的患者进行了前瞻性队列研究。患者在 9 个月内完成了 3 次研究访问。微量白蛋白尿的定义为女性 25-355mg/g 及男性 17-250mg/g 的几何均数 ACR。
微量白蛋白尿的患病率为 14%。单次尿液 ACR 测定的阴性预测值为 98%,而阳性预测值仅为 74%。黑人和非黑人患者(15%和 14%)的微量白蛋白尿发生率相似(p=0.8)。微量白蛋白尿患者更易患有高血压(p=0.02)和代谢综合征(p=0.03)。尽管两组患者的 HIV 感染持续时间和 HIV 病毒载量相似,但微量白蛋白尿患者的 CD4 计数<200 个细胞/μl 的可能性更大(p=0.0003)。在多变量逻辑回归分析中,微量白蛋白尿的唯一显著独立预测因素是低 CD4 计数(p=0.018)和目前利托那韦暴露(p=0.04)。
感染艾滋病毒的临床人群中微量白蛋白尿的患病率与早期报告相似,与高血压和免疫功能受损有关。单次正常 ACR 测定可有效排除微量白蛋白尿,而升高的 ACR 需要确认。